Myostatin and follistatin: what the science actually says about muscle genetics

What did @nomade_marombeiro actually say?

Honestly, parsing this one is a challenge. The transcript is largely unintelligible, a mix of Portuguese fragments and what appears to be machine-transcription noise. The clearest signal is the caption and hashtags: the creator intended to explain myostatin and follistatin, their roles in muscle hypertrophy, and how genetic variation in these proteins affects muscle growth. The phrase "regulador negativo do crescimento muscular" appears embedded in the garbled text, which would be an accurate description of myostatin's function. Beyond that, no specific quantitative claims, dosing suggestions, or peptide recommendations can be reliably extracted from the transcript itself.

The video is categorized under peptide therapy on this platform, which is worth flagging. Neither myostatin nor follistatin are peptides in the clinical sense used in that category, and the creator does not appear to be pushing a product. That said, this topic is frequently used as a gateway to promote follistatin peptide supplements or gene therapies of dubious legitimacy, so the context matters.

Does the science back this up?

The underlying biology, to the extent we can reconstruct the creator's intended claims, is well-supported. Myostatin is real, its inhibitory role is documented, and follistatin's ability to bind and neutralize myostatin has been replicated across multiple model systems. This is not fringe science.

Myostatin, encoded by the MSTN gene, is a member of the TGF-beta superfamily and acts as a negative regulator of skeletal muscle mass. This was established clearly in the landmark knockout mouse study by McPherron et al. (1997, Nature), where MSTN-null mice showed roughly double the muscle mass of wild-type controls. Follistatin (FST) is an endogenous antagonist that binds myostatin and several other TGF-beta ligands, effectively blunting their signaling. Human data from Matsakas and Diel (2005, Journal of Musculoskeletal and Neuronal Interactions) confirmed that natural variation in MSTN and FST expression partially explains inter-individual differences in hypertrophic response to resistance training. The genetic angle the creator gestures toward is legitimate, though the effect sizes in human populations are modest compared to the dramatic animal model results.

What did they get wrong (or right)?

Credit where it is due: framing myostatin as a "negative regulator" of muscle growth is correct, and connecting genetic variation to differential hypertrophic responses is a reasonable, evidence-grounded point. These are things most fitness content creators either ignore entirely or get catastrophically wrong.

What is harder to assess is whether the creator oversimplified the follistatin side of the equation. Follistatin does not exclusively target myostatin. It also binds activin A, GDF-11, and other TGF-beta family members with real physiological consequences, including effects on reproduction, bone metabolism, and inflammation. Presenting follistatin purely as a "muscle growth accelerator" misses that complexity, and this omission matters because it feeds into the marketing narrative around follistatin peptide supplements, which are sold with exactly that reductive framing. Schuelke et al. (2004, New England Journal of Medicine) documented the now-famous case of a child with a loss-of-function MSTN mutation, which generated enormous public interest but also substantial misinterpretation about what myostatin inhibition means clinically in adults.

What should you actually know?

The myostatin-follistatin axis is genuinely interesting biology, but the gap between animal models and practical human application is large and frequently exploited. Here is what the evidence actually supports.

• Loss-of-function MSTN mutations produce dramatic muscle phenotypes in cattle, dogs, and at least one documented human case, but these are rare and not replicable through supplementation.
• Follistatin peptide products marketed for muscle growth are not the same as endogenous follistatin. The assumption that exogenous administration produces equivalent effects is unsupported by human clinical trial data.
• Resistance training itself modulates myostatin expression. A meta-analysis by Diel et al. (2014, Journal of Applied Physiology) found that acute and chronic resistance training reduces circulating myostatin levels, meaning you already have a proven intervention.
• Genetic testing for MSTN variants is commercially available but has low predictive value for individual hypertrophic response in the general population. Do not make training or supplementation decisions based on these tests alone.
• If you are considering any peptide or experimental compound that claims to target this pathway, that conversation belongs with a licensed clinician reviewing your full health history, not a TikTok comment section.

Bottom line

The science of myostatin and follistatin is real and worth understanding. A TikTok with a largely unintelligible transcript is not the place to learn it rigorously, but the creator does not appear to be making dangerous or fraudulent claims based on what can be decoded. The risk here is less about what was said and more about the broader ecosystem this content feeds: supplement marketers who use legitimate biology to sell products that have not cleared the bar of human clinical evidence.